Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

Gautam Borthakur; E. Lin; Nitin Jain; Elihu E. Estey; Jorge E. Cortes; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Sherry Pierce; Hagop Kantarjian

doi:10.1002/cncr.24367

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

Gautam Borthakur, E. Lin, Nitin Jain, Elihu E. Estey, Jorge E. Cortes, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Sherry Pierce, Hagop Kantarjian

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Abstract

BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with corebinding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.

Original language	English (US)
Pages (from-to)	3217-3221
Number of pages	5
Journal	Cancer
Volume	115
Issue number	14
DOIs	https://doi.org/10.1002/cncr.24367
State	Published - 2009
Externally published	Yes

Keywords

Acute myelogenous leukemia
Core-binding factor
Event-free survival
Matched analysis
Overall survival
Therapy-related

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cncr.24367

Cite this

@article{9d8a591eaa4641cbb0d3873ae425b195,

title = "Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia",

abstract = "BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with corebinding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.",

keywords = "Acute myelogenous leukemia, Core-binding factor, Event-free survival, Matched analysis, Overall survival, Therapy-related",

author = "Gautam Borthakur and E. Lin and Nitin Jain and Estey, {Elihu E.} and Cortes, {Jorge E.} and Susan O'Brien and Stefan Faderl and Farhad Ravandi and Sherry Pierce and Hagop Kantarjian",

year = "2009",

doi = "10.1002/cncr.24367",

language = "English (US)",

volume = "115",

pages = "3217--3221",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "14",

}

TY - JOUR

T1 - Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

AU - Borthakur, Gautam

AU - Lin, E.

AU - Jain, Nitin

AU - Estey, Elihu E.

AU - Cortes, Jorge E.

AU - O'Brien, Susan

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Pierce, Sherry

AU - Kantarjian, Hagop

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with corebinding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.

AB - BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with corebinding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.

KW - Acute myelogenous leukemia

KW - Core-binding factor

KW - Event-free survival

KW - Matched analysis

KW - Overall survival

KW - Therapy-related

UR - http://www.scopus.com/inward/record.url?scp=68549123422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549123422&partnerID=8YFLogxK

U2 - 10.1002/cncr.24367

DO - 10.1002/cncr.24367

M3 - Article

C2 - 19441109

AN - SCOPUS:68549123422

SN - 0008-543X

VL - 115

SP - 3217

EP - 3221

JO - Cancer

JF - Cancer

IS - 14

ER -

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this